BATON ROUGE, La. (AP) -- A pharmaceutical company based in Baton Rouge plans to begin manufacturing protein-based drugs in Europe over the next two years.
TransGenRx CEO William Fioretti says the company will boost its employment in Baton Rouge from 38 to about 60 during that time. The company was founded in 2002.
One of the company's goals is to produce generic drugs at lower than current costs. Fioretti told The Advocate that the European Union offers a regulatory system for approving generic versions of drugs in as little as six months -- as compared with the years sometimes required to get U.S. approval.
